Xarelto on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms XaMINA
- Sponsors Bayer
- 13 Mar 2018 Planned End Date changed from 30 Sep 2019 to 31 Dec 2019.
- 13 Oct 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 New trial record